Kashif Chaudhry

Principal

Anthony Hsiao

Principal

Kashif Chaudhry

Principal

Anthony Hsiao

Principal

Role

Kashif leads all US based workstreams and serves a key thought partner for Chinese life science companies looking to partner with or self-commercialize their products in the United States.

Expertise

Kashif is a strategic leader in the biopharma and medical devices industry, with special expertise in developing commercial strategy and launch readiness plans for his clients. His expertise spans several decades of helping his clients maximizing the commercial potential of their clinical assets, whether through internal or external means. He has supported both large MNC corporations in conducting M&A due diligence as well as emerging biopharma companies seeking strategic partnerships or self-commercializing their products.

Prior Experience

Kashif was Senior Principal of Launch Readiness at IQVIA (IMS Consulting Group), where he oversaw the commercial strategy development for his clients, with a particular focus in emerging biopharmaceutical companies preparing for their first commercial launch or co-promotion partnership. He also spent over a decade as Managing Director of Clarescent, a boutique consulting firm specializing in market research and analytics in the life sciences industry.

Education

Kashif holds an MBA from the Kellogg School of Management at Northwestern, and a B.S. in electrical engineering from the Johns Hopkins University

Role

Anthony leads all cross-border collaborations and deals between Chinese and ex-China (US, EU, Japan, etc.) clients. He is responsible for the facilitation and delivery of global workstreams.

Expertise

Anthony is a proven strategic thought partner to life science companies and investment firms. He has 15 years of experience advising pharmaceutical and biotech companies, as well as financial institutions and academic research institutions. He specializes in financial forecasting and transactional support, particularly for clinical stage companies exploring commercialization options.

 

Anthony specializes in US-China cross-border deals and partnerships. He currently resides in Hong Kong, with frequent travel to Shanghai, the SF Bay Area, and NYC. He is experienced representing both US and Chinese client interests and understands the nuances of the language and culture associated with both.

Prior Experience

Anthony has experience working both in industry and as an external consultant. Previously, he was served as the HCP strategy lead for Gilead’s HIV portfolio, where he partnered with multiple consulting firms to develop commercial roadmaps and forecasts. Anthony also spent many years as a strategy consultant, at both IQVIA (formerly IMS Consulting) and Deloitte Consulting (formerly Monitor). As a consultant, Anthony worked with dozens of MNC’s, emerging biopharma companies, and financial institutions looking to commercialize assets in the greater China region.

Education

Anthony holds an MBA from Columbia Business School, and a B.S. in pharmaceutical chemistry from the University of California at Davis.

Role

Kashif leads all US based workstreams and serves a key thought partner for Chinese life science companies looking to partner with or self-commercialize their products in the United States.

Expertise

Kashif is a strategic leader in the biopharma and medical devices industry, with special expertise in developing commercial strategy and launch readiness plans for his clients. His expertise spans several decades of helping his clients maximizing the commercial potential of their clinical assets, whether through internal or external means. He has supported both large MNC corporations in conducting M&A due diligence as well as emerging biopharma companies seeking strategic partnerships or self-commercializing their products.

Prior Experience

Kashif was Senior Principal of Launch Readiness at IQVIA (IMS Consulting Group), where he oversaw the commercial strategy development for his clients, with a particular focus in emerging biopharmaceutical companies preparing for their first commercial launch or co-promotion partnership. He also spent over a decade as Managing Director of Clarescent, a boutique consulting firm specializing in market research and analytics in the life sciences industry.

Education

Kashif holds an MBA from the Kellogg School of Management at Northwestern, and a B.S. in electrical engineering from the Johns Hopkins University

Role

Anthony leads all cross-border collaborations and deals between Chinese and ex-China (US, EU, Japan, etc.) clients. He is responsible for the facilitation and delivery of global workstreams.

Expertise

Anthony is a proven strategic thought partner to life science companies and investment firms. He has 15 years of experience advising pharmaceutical and biotech companies, as well as financial institutions and academic research institutions. He specializes in financial forecasting and transactional support, particularly for clinical stage companies exploring commercialization options.

 

Anthony specializes in US-China cross-border deals and partnerships. He currently resides in Hong Kong, with frequent travel to Shanghai, the SF Bay Area, and NYC. He is experienced representing both US and Chinese client interests and understands the nuances of the language and culture associated with both.

Prior Experience

Anthony has experience working both in industry and as an external consultant. Previously, he was served as the HCP strategy lead for Gilead’s HIV portfolio, where he partnered with multiple consulting firms to develop commercial roadmaps and forecasts. Anthony also spent many years as a strategy consultant, at both IQVIA (formerly IMS Consulting) and Deloitte Consulting (formerly Monitor). As a consultant, Anthony worked with dozens of MNC’s, emerging biopharma companies, and financial institutions looking to commercialize assets in the greater China region.

Education

Anthony holds an MBA from Columbia Business School, and a B.S. in pharmaceutical chemistry from the University of California at Davis.

职责

Kashif负责在美国的业务流程，也是在美国寻求合作或自行实现产品商业化的中国生命科学公司的重要思想伙伴。

专业领域

Kashif是生物制药和医疗设备行业的战略领导者，特别擅长为客户制定商业战略和上市准备计划。数十年来，他帮助客户通过内部或外部途径最大限度地发挥其临床资产的商业潜力。他既有支持大型跨国公司进行并购尽职调查的经历，也曾服务于新兴生物制药公司，帮助他们寻求战略合作或实现产品的商业化。

个人资历

Kashif曾在IQVIA（IMS咨询集团）担任上市准备工作的高级负责人，负责监督客户的商业战略发展，尤其关注新兴生物制药公司并为这些公司的首次商业上市或合作推广做准备。他还在Clarescent担任过十多年的董事总经理，这是一家专门从事生命科学行业市场研究和分析的专业咨询公司。

教育背景

Kashif 拥有美国西北大学凯洛格管理学院的MBA学位，以及约翰霍普金斯大学的电子工程学士学位。

角色

肖安东负责中国与非中国（美国、欧盟、日本等）客户之间的全部跨境合作和交易，并负责创建和促进全球工作流程。

专长

肖安东是广受生命科学公司和投资公司认可的战略思想伙伴。他专注为制药和生物技术公司、金融机构和学术研究机构提供咨询服务，并为之深耕15年。他擅长财务预测和交易支持，尤其善于为探索商业化方案的临床阶段公司提供宝贵建议。

 

肖安东擅长中美跨境交易和伙伴关系合作。他目前居住在香港，并经常往返于上海、旧金山湾区和纽约市。他拥有服务美国和中国客户的丰富经历，并了解两类客户在语言和文化上的细微差别。

从业经验

肖安东曾投身行业企业，也曾担任企业的外部顾问。此前，他是吉利德公司HIV 产品组合的HCP战略负责人，与多家咨询公司合作制定商业路线图并预测发展前景。肖安东还在IQVIA（原IMS咨询公司）和德勤咨询公司（原Monitor）担任过多年的战略顾问。肖安东也曾以顾问的角色与寻求在大中华地区实现资产商业化的数十家跨国公司、新兴生物制药公司和金融机构合作。

教育背景

肖安东获得哥伦比亚商学院的MBA学位，以及加利福尼亚大学戴维斯分校的药物化学学士学位。